Generic Drugs Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

The Report Covers the Global Generic Drug Market Size, Trends, and Share and is Segmented by Route of Administration (Oral, Topical, Injectable, and Other Routes of Administration), Application (Cardiovascular Products, Anti-Infective Drugs, Central Nervous System Drugs, Anti-Cancer Drugs, Respiratory Products, and Other Applications), Distribution Channel (Hospitals/Clinics, Retail Pharmacies, and Other Distribution Channels), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The Report Offers the Value (USD) for the Above Segments.

Generic Drugs Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

Generic Drugs Market Size

Generic Drugs Market Summary
Study Period 2021 - 2030
Market Size (2025) USD 431.10 Billion
Market Size (2030) USD 530.32 Billion
CAGR (2025 - 2030) 4.23 %
Fastest Growing Market Asia-Pacific
Largest Market North America
Market Concentration Medium

Major Players

Generic Drugs Market Major Players

*Disclaimer: Major Players sorted in no particular order

Compare market size and growth of Generic Drugs Market with other markets in Healthcare Industry

Biotechnology

Pharmaceuticals

Healthcare IT

Medical Devices

Animal Health

Device Drug Combination

Generic Drugs Market Analysis

The Generic Drugs Market size is estimated at USD 431.10 billion in 2025, and is expected to reach USD 530.32 billion by 2030, at a CAGR of 4.23% during the forecast period (2025-2030).

The rising prevalence of chronic diseases has spurred the demand for affordable medications, driving the Generic Medicine Market. Their lower cost, compared to branded alternatives, is a significant factor fueling their adoption in developing and developed economies. Additionally, as patents expire on blockbuster drugs, the market is witnessing a surge in the development of generic versions, further propelling the growth of the Generic Pharmaceuticals Market.

Chronic diseases such as diabetes, cardiovascular diseases, respiratory diseases, and various cancers require ongoing medication use. The high prevalence of cardiovascular diseases is propelling the growth of the Generic Drugs Market. For instance, coronary artery disease has risen at a high rate in recent years. According to a report published by the Centers for Disease Control and Prevention in May 2023, coronary heart disease is the most prevalent form of heart disease. Approximately 5% of adults aged 20 years and older, or one in 20, are affected by coronary artery disease (CAD) globally.

According to the same source, every year, about 850,000 people in the United States have a heart attack. Among these, 605,000 have had their first heart attack, and over 200,000 people have already had a heart attack. This presents a substantial market opportunity for the United States Generic Drugs Market, as the demand for cost-effective medications used during treatment contributes significantly to the growth of the Generic Drugs Market.

Moreover, the increasing prevalence of diabetes cases worldwide is projected to drive the global rise in diabetes cases and is expected to propel market growth during the forecast period. For instance, according to a report published by the Institute for Health Metrics and Evaluation in June 2023, the number of diabetes cases is projected to increase from 529 million in 2022 to 1.3 billion by 2050. The rising prevalence of chronic diseases is anticipated to drive the demand for effective treatments, thereby propelling the growth of the Global Generic Drugs Market during the forecast period. Furthermore, the implementation of various organic and inorganic strategies by key market players is expected to bolster market expansion. For instance, in May 2024, Gland Pharma Limited, Hikma Pharmaceuticals USA Inc., Long Grove Pharmaceuticals LLC, and Dr. Reddy's Laboratories Limited received approval for Edaravone Intravenous Solutions intended for the treatment of amyotrophic lateral sclerosis, a progressive neurodegenerative disease which is a generic alternative of Radicava, contributing to the expansion of the Generic Drug Manufacturing sector.

In conclusion, the increasing incidence of chronic diseases, combined with the strategic initiatives of leading industry players, is projected to significantly enhance the growth of the Generic Pharmaceutical Industry in the coming years.

However, stringent government regulations and a short supply of generic drugs in the market are expected to restrain market growth during the forecast period.

Generic Drugs Industry Overview

The global Generics Industry is highly competitive, with many players dominating the market. The market players are adopting strategies such as rising R&D investment, mergers, acquisitions, and product innovations to sustain the increasing market rivalry. The key market players include Mylan NV, Eli Lilly and Company, GlaxoSmithKline PLC, Pfizer Inc., Sun Pharmaceutical Industries Ltd., Novartis AG, and Sanofi.

Generic Drugs Market Leaders

  1. Sanofi

  2. Pfizer

  3. Teva Pharmaceutical Industries Limited

  4. Abbott Laboratories

  5. Sun Pharmaceutical Industries Ltd.

  6. *Disclaimer: Major Players sorted in no particular order
 Generic Drugs Market Concentration
Need More Details on Market Players and Competiters?
Download PDF

Generic Drugs Market News

  • May 2024: Dr. Reddy's Laboratories introduced a generic medication, Doxycycline Capsules (40 mg), to the US market. This medication is designed to combat a broad spectrum of bacterial infections. Notably, the product serves as a therapeutic generic alternative to the USFDA-approved Oracea capsules (40 mg).
  • January 2024: SinoT received approval for its generic drug Posaconazole delayed-release tablets from Health Canada. Posaconazole is a member of the group of triazole antifungals, which is used to prevent certain kinds of fungal or yeast infections.

Generic Drugs Market Report - Table of Contents

1. INTRODUCTION

  • 1.1 Study Assumption and Market Definition
  • 1.2 Scope of the Study

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Prevalence of Chronic Diseases
    • 4.2.2 Rise in Geriatric Population
    • 4.2.3 Increase in Healthcare Expenditure
  • 4.3 Market Restraints
    • 4.3.1 Stringent Government Regulations
    • 4.3.2 Adverse Effects Associated With the Drugs
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5. MARKET SEGMENTATION (Market Size by Value - USD)

  • 5.1 By Route of Administration
    • 5.1.1 Oral
    • 5.1.2 Topical
    • 5.1.3 Injectable
    • 5.1.4 Other Routes of Administration (Sublingual, Rectal)
  • 5.2 By Application
    • 5.2.1 Cardiovascular Products
    • 5.2.2 Anti-infective Drugs
    • 5.2.3 Anti-arthritis Drugs
    • 5.2.4 Central Nervous System Drugs
    • 5.2.5 Anti-cancer Drugs
    • 5.2.6 Respiratory Products
    • 5.2.7 Other Applications (Gastrointestinal, Hormonal Drug)
  • 5.3 By Distribution Channel
    • 5.3.1 Hospitals/Clinics
    • 5.3.2 Retail Pharmacies
    • 5.3.3 Other Distribution Channels (Online Pharmacy, Specialty Drug Stores)
  • 5.4 By Geography
    • 5.4.1 North America
    • 5.4.1.1 United States
    • 5.4.1.2 Canada
    • 5.4.1.3 Mexico
    • 5.4.2 Europe
    • 5.4.2.1 United Kingdom
    • 5.4.2.2 Germany
    • 5.4.2.3 France
    • 5.4.2.4 Italy
    • 5.4.2.5 Spain
    • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia-Pacific
    • 5.4.3.1 China
    • 5.4.3.2 Japan
    • 5.4.3.3 India
    • 5.4.3.4 Australia
    • 5.4.3.5 South Korea
    • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle East and Africa
    • 5.4.4.1 GCC
    • 5.4.4.2 South Africa
    • 5.4.4.3 Rest of Middle East and Africa
    • 5.4.5 South America
    • 5.4.5.1 Brazil
    • 5.4.5.2 Argentina
    • 5.4.5.3 Rest of South America

6. COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Mylan (Viatris Inc.)
    • 6.1.2 Abbott Laboratories
    • 6.1.3 Teva Pharmaceutical Industries Limited
    • 6.1.4 Eli Lilly and Company
    • 6.1.5 STADA Arzneimittel AG
    • 6.1.6 GlaxoSmithKline PLC
    • 6.1.7 Baxter International Inc.
    • 6.1.8 Pfizer Inc.
    • 6.1.9 Sanofi
    • 6.1.10 Sun Pharmaceutical Industries Ltd
    • 6.1.11 AbbVie Inc. (Allergan)
  • *List Not Exhaustive

7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape Covers- Business Overview, Financials, Products and Strategies, and Recent Developments
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Generic Drugs Industry Segmentation

As per the scope of this report, a generic drug is a pharmaceutical drug that contains the same chemical substance as that used for the patented molecule. A generic drug is only allowed onto the market when its original drug's patent period expires. It is a molecule now allowed to be sold by all the players under a different brand name. The generic drugs market is segmented by route of administration, application, distribution channel, and geography. The route of administration segment is further divided into oral, topical, injectable, and other routes of administration. The application segment is further segmented into cardiovascular products, anti-infective drugs, central nervous system drugs, anti-cancer drugs, respiratory products, and other applications. The end user segment is further bifurcated into hospitals/clinics, retail pharmacies, and other distribution channels. The geography segment is further divided into North America, Europe, Asia-Pacific, Middle East and Africa, and South America. The market report also covers the estimated market sizes and trends for 17 different countries across major regions globally. The report offers the value (USD) for the above segments.

By Route of Administration Oral
Topical
Injectable
Other Routes of Administration (Sublingual, Rectal)
By Application Cardiovascular Products
Anti-infective Drugs
Anti-arthritis Drugs
Central Nervous System Drugs
Anti-cancer Drugs
Respiratory Products
Other Applications (Gastrointestinal, Hormonal Drug)
By Distribution Channel Hospitals/Clinics
Retail Pharmacies
Other Distribution Channels (Online Pharmacy, Specialty Drug Stores)
By Geography North America United States
Canada
Mexico
Europe United Kingdom
Germany
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa GCC
South Africa
Rest of Middle East and Africa
South America Brazil
Argentina
Rest of South America
Need A Different Region or Segment?
Customize Now

Generic Drugs Market Research FAQs

How big is the Generic Drugs Market?

The Generic Drugs Market size is expected to reach USD 431.10 billion in 2025 and grow at a CAGR of 4.23% to reach USD 530.32 billion by 2030.

What is the current Generic Drugs Market size?

In 2025, the Generic Drugs Market size is expected to reach USD 431.10 billion.

Who are the key players in Generic Drugs Market?

Sanofi, Pfizer, Teva Pharmaceutical Industries Limited, Abbott Laboratories and Sun Pharmaceutical Industries Ltd. are the major companies operating in the Generic Drugs Market.

Which is the fastest growing region in Generic Drugs Market?

Asia-Pacific is estimated to grow at the highest CAGR over the forecast period (2025-2030).

Which region has the biggest share in Generic Drugs Market?

In 2025, the North America accounts for the largest market share in Generic Drugs Market.

What years does this Generic Drugs Market cover, and what was the market size in 2024?

In 2024, the Generic Drugs Market size was estimated at USD 412.86 billion. The report covers the Generic Drugs Market historical market size for years: 2021, 2022, 2023 and 2024. The report also forecasts the Generic Drugs Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.

Generic Medicines Industry Report

This comprehensive report offers a deep dive into the generic drugs industry, providing a detailed analysis of key market drivers and market segments. Mordor Intelligence offers customization based on your specific interests, including: 1. Route of Administration: Parental and Inhalers 2. Application: Dermatology, Oncology, Rheumatology, and Genitourinary/Hormonal 3. End-Users: Hospitals, Homecare, and Specialty Clinics